Amgen to Buy Horizon in Biotech’s Biggest Deal of 2022

Amgen has emerged the winner in a three-way contest to buy rare disease giant Horizon Therapeutics, confirming Monday morning it will acquire the Irish company for $26.4 billion.

The California-based biotech leader will pay $116.50 for each share of Horizon, according to Reuters. Struck just three weeks before the close of 2022, it is biopharma’s largest deal of the year.